Sarah Cannon, the Cancer Institute of HCA Healthcare, announced that Navneet Majhail, MD, MS, FASTCT, has been named Deputy Physician-in-Chief of Blood Cancers for the Sarah Cannon Transplant and Cellular Therapy Network (formerly the Sarah Cannon Blood Cancer Network). In his role, Dr. Majhail will focus on the continued expansion of the Sarah Cannon Transplant and Cellular Therapy Network Centers of Excellence, providing increased access for patients in the communities served by Sarah Cannon.
In addition to his work at Sarah Cannon, Dr. Majhail will serve as Program Medical Director for the Sarah Cannon Transplant and Cellular Therapy Program at Centennial Medical Center in Nashville. Dr. Majhail will formally begin his position in late September 2021.
“We are delighted that Dr. Majhail is joining Sarah Cannon and will work alongside our teams to foster an increased collaboration across our six U.S. and three UK blood cancer programs,” said Fred LeMaistre, MD, Senior Vice President, Sarah Cannon Market Operations and Physician-in-Chief of Blood Cancers. “His incredible depth and breadth of experience, not only at the bedside, but also as a strategic thinker, researcher, and coupled with his experience in regulatory and policy issues, will bring great value to our Network and the patients we serve.”
Dr. Majhail currently serves as Director of the Cleveland Clinic’s Blood and Marrow Transplant Program, while also serving as Vice Chair for the Department of Hematology and Medical Oncology and Professor of Medicine with the Cleveland Clinic Lerner College of Medicine.
He is a Past President of the American Society for Transplantation and Cellular Therapy (ASTCT) and has been recognized as a fellow for his contributions to the field of transplantation and cellular therapy. He is a respected thought leader in health outcomes research and has published extensively on the prevention and management of early and late complications of hematopoietic cell transplantation and health policy issues such as health-care disparities, quality of care, survivorship, and economic issues related to transplantation and cellular therapy.
Dr. Majhail received his bachelor of medicine and bachelor of surgery (MBBS) from the Government Medical College & Hospital in Chandigarh, India, and his medical degree (MD) in radiation oncology from the All India Institute of Medical Sciences in New Delhi. He completed his residency in internal medicine at the Cleveland Clinic Foundation, his master of science (MS) in clinical research at the School of Public Health at the University of Minnesota, and his fellowship in hematology/oncology at the University of Minnesota.